I am a Senior Principal Scientist in Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), responsible for setting the research strategy and building a strong early pipeline of projects in heart failure.

A cardiologist by training, I received my medical degree from Shandong University, China, following which I worked as clinical cardiologist and lecturer. After obtaining a PhD in Cardiology from Karolinska Institute, I joined AstraZeneca in 1997.

During my first few years at AstraZeneca, I provided cardiovascular pharmacology support to several late stage projects across therapeutic areas whilst also developing several preclinical models of heart failure. Later, I initiated and developed the cardiac regeneration programme at AstraZeneca. Through my time at the company, I have led many cardiovascular projects including small molecule, protein and RNA projects.

I have also led a number of successful collaborations with academic and industry partners and have published 63 peer-reviewed papers, including papers in high impact journals such as Nature Medicine, Nature Communications, Cell Research and Circulation.

My work is focused on discovering and developing potential new medicines for heart failure patients. Despite therapeutic advances, heart failure remains as life-threatening as most common forms of cancer. Working at the cutting edge of science is what motivates me.

Qing-Dong Wang Senior Principal Scientist, Bioscience, Research and Early Development, CVRM, BioPharmaceuticals R&D




















Reassessment of c-Kit+ Cells for Cardiomyocyte Contribution in Adult Heart英雄联盟主播投注

He L, Han M, Zhang Z et al. Circulation. 2019;140:164–166

Publication link:https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.039909

Genetic Tracing Identifies Early Segregation of the Cardiomyocyte and Non-Myocyte Lineages.英雄联盟主播投注

Li Y, Lv Z, He L et al. Circulation research. Publication link: https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.119.315280


Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway.英雄联盟主播投注

Mills RJ, Parker BL, Quaife-Ryan GA et al. Cell Stem Cell. 2009; 24(6): 895-907. Publication link: https://www.cell.com/cell-stem-cell/fulltext/S1934-5909%2819%2930108-0

Enhancing the precision of genetic lineage tracing using dual recombinases.英雄联盟主播投注

He L, Li Y, Li Y et al. Nature Medicine. 2017; 23: 1488-98.

Publication link: https://www.nature.com/文章s/nm.4437

Identification of a hybrid myocardial zone in the mammalian heart after birth. 英雄联盟主播投注

Tian X, Li Y, He L et al. Nature Communications. 2017; 8:87.

Publication link: https://www.nature.com/文章s/s41467-017-00118-1

An IGF1R-dependent pathway drives epicardial adipose tissue formation after myocardial injury.英雄联盟主播投注

Zangi L, Oliveira MS, Ye LL et al. Circulation. 2017;135:59-72

Publication link: https://www.ncbi.nlm.nih.gov/pmc/文章s/PMC5195872/

Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions.英雄联盟主播投注

Bao X, Lian X, Hacker TA et al. Nature Biomedical Engineering. 2016;1. pii: 0003.

Publication link: https://www.nature.com/文章s/s41551-016-0003

Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic modalities.英雄联盟主播投注

Plowright AT, Engkvist O, Gill A, Knerr L, Wang QD. Angewandte Chemie International Edition. 2014,53,4056-75

Publication link: https://onlinelibrary.wiley.com/doi/full/10.1002/anie.201307034


and help us deliver life-changing medicines 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.